Holen Sie sich die Stockscreener-App
1.55
6.06%
-0.10
Handel nachbörslich:
1.60
0.05
+3.23%
iBio Inc Aktie (IBIO) Neueste Nachrichten
Top iBio (IBIO) Competitors 2026 - MarketBeat
Could iBio (IBIO) Be an Underrated Obesity Stock? - Insider Monkey
5 Under-the-Radar AI Stocks to Buy in 2026 - Insider Monkey
iBio Inc. (IBIO) Nears Key Support Amid Slight Decline: Technical AnalysisQuote Data - newsline.com
IBIO Initiates Coverage On Raymond James -- Rating Set to Outper - GuruFocus
IBIO Initiates Coverage On Raymond James -- Rating Set to Outperform - GuruFocus
Raymond James initiates iBio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Raymond James Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $5 - Moomoo
Raymond James initiates iBio stock coverage with outperform rating - Investing.com
B. Riley Initiates IBio at Buy With $6 Price Target - Moomoo
IBIO: Advancing antibody-based therapies for obesity, muscle preservation, and weight maintenance - TradingView
IBIO: Advancing antibody-based therapies for obesity and weight maintenance with key clinical milestones ahead - TradingView
iBio to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
AI drug developer iBio joins two health investor events in June and July 2026 - Stock Titan
iBio doses first patient in obesity drug trial - Investing.com UK
iBio (IBIO) Begins Phase 1 Clinical Trial for IBIO-600 - GuruFocus
iBio doses first patient in obesity drug trial By Investing.com - Investing.com Australia
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity - The Manila Times
iBio tests long-acting obesity antibody designed to preserve muscle - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $6 - 富途牛牛
IBIO - Finviz
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
$IBIO stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
iBio (IBIO) director receives 60,000 stock options vesting over 3 years - Stock Titan
LifeSci Capital Remains a Buy on Ibio (IBIO) - The Globe and Mail
Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO) - The Globe and Mail
Logos Global reports zero ownership in iBio (NASDAQ: IBIO) - Stock Titan
Point72, Steven A. Cohen report 0% in iBio (IBIO) amendment - Stock Titan
EcoR1 and Oleg Nodelman report 1.58M shares in iBio (NASDAQ: IBIO) - Stock Titan
Cormorant (IBIO) reports 3.83M shares, holds near-10% via warrants - Stock Titan
iBio (NASDAQ: IBIO) — Sirenia/Manager report 11.59M shares, near 10% cap - Stock Titan
Elizabeth Stoner joins iBio (IBIO) board and files initial Form 3 - Stock Titan
We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate - Yahoo Finance
iBio (IBIO) adviser and manager report a 9.99% beneficial stake - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Insider Traders Lose US$19k As iBio Drops - simplywall.st
iBio, Inc. Stock 12‑Month Price Target Raised to $5.53, Implies 244% Upside - TradingView
IBio 3Q Rev $0.00 >IBIO - Moomoo
Intelligent Bio Solutions Reports 46% Revenue Growth in Q3 FY202 - GuruFocus
IBIO Achieves Key Milestones in Obesity Treatment Development - GuruFocus
IBio 3Q Loss $7.73M >IBIO - Moomoo
IBio reports Q3 fiscal year 2026 financial results and provides corporate update - marketscreener.com
iBio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Frazier funds disclose holdings and warrants in iBio (NASDAQ: IBIO) - Stock Titan
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):